MedTrace Logo

Study to Evaluate Home Vision Testing in Participants Who Receive Ranibizumab (Lucentis®)

NCT02420132 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 47

Last updated 2019-06-10

No results posted yet for this study

Summary

This pilot study will evaluate home vision testing using a mobile medical application in participants with diabetic macular edema (DME) or neovascular age-related macula degeneration (nAMD) who receive intravitreal ranibizumab therapy. In the main, decentralized study, participants will be recruited via digital media, advocacy groups, or through their own ophthalmologist. The traditional substudy will evaluate the association between visual acuity and anatomical markers of disease status determined using clinical "gold standard" assessments (certified Early Treatment Diabetic Retinopathy Study \[ETDRS\] protocol visual acuity and macula optical coherence tomography \[OCT\]) and the results of home vision testing using the myVisionTrack\^TM (mVT) application.

Conditions

  • Macular Edema
  • Macular Degeneration

Interventions

OTHER

Ranibizumab

Ranibizumab administered as part of standard-of-care

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-20
Primary Completion
2016-08-25
Completion
2016-08-25

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02420132 on ClinicalTrials.gov